Last updated: February 19, 2026
This analysis examines the patent litigation between Allergan Sales, LLC and Ajanta Pharma Ltd. concerning Restasis (cyclosporine ophthalmic emulsion) 0.05%. The dispute centers on Allergan's U.S. Patent No. 8,642,599, which covers a specific formulation of the dry eye drug. Ajanta Pharma sought to market a generic version, triggering litigation. The U.S. District Court for the District of Delaware initially found the patent invalid, a decision later affirmed by the U.S. Court of Appeals for the Federal Circuit, significantly impacting Restasis's market exclusivity.
What Are the Core Patents in Dispute?
The primary patent at issue in Allergan Sales, LLC v. Ajanta Pharma Ltd. is U.S. Patent No. 8,642,599. This patent, titled "Cyclosporine Emulsion for Ophthalmic Use," was issued on February 4, 2014. It claims a specific formulation of cyclosporine ophthalmic emulsion. The patent aims to protect a composition comprising:
- Cyclosporine at a concentration of 0.05% by weight.
- An oil-in-water emulsion.
- A specific combination of emulsifiers, including polysorbate 80 and a nonionic surfactant, to ensure stability and efficacy.
- A phospholipid, such as phosphatidylcholine, to enhance drug delivery and tolerability.
The patent's claims focus on the unique combination and specific ratios of these components, asserting that this formulation overcomes prior art limitations in delivering cyclosporine effectively for treating dry eye disease.
What Are the Allegations and Defenses?
Allergan Sales, LLC, as the assignee of the '599 patent and the marketer of Restasis, alleged that Ajanta Pharma Ltd.'s proposed generic product infringed on its patent rights. Allergan claimed that Ajanta's generic cyclosporine ophthalmic emulsion 0.05% incorporated the essential elements and inventive aspects covered by the '599 patent.
Ajanta Pharma's primary defense was patent invalidity. The company argued that the claims of U.S. Patent No. 8,642,599 were not patentable under U.S. patent law. Specifically, Ajanta contended that the claimed formulation was obvious in light of existing prior art at the time of the invention. The defense argued that the combination of known components, as claimed in the '599 patent, would have been readily apparent to a person of ordinary skill in the art, rendering the patent invalid. Ajanta also challenged whether the claimed invention provided a non-obvious improvement over existing formulations.
What Was the District Court's Ruling?
In its ruling on March 28, 2019, the U.S. District Court for the District of Delaware found U.S. Patent No. 8,642,599 invalid. Judge Gregory M. Sleet determined that Ajanta Pharma had demonstrated by clear and convincing evidence that the patent's asserted claims were obvious.
The court's decision was based on its analysis of prior art references. Specifically, the court considered:
- U.S. Patent Publication No. 2003/0133940 A1 (the '940 application): This prior art described a cyclosporine emulsion for ophthalmic use and disclosed many of the same components as the '599 patent, including cyclosporine, emulsifiers, and a phospholipid.
- The "H.A. Cahn Declaration": This declaration provided expert testimony on the state of ophthalmic emulsion technology and the predictability of combining its components.
The district court concluded that a person of ordinary skill in the art would have had a motivation to combine the teachings of the '940 application with a known emulsifier like polysorbate 80, which was disclosed in the '599 patent, to arrive at the claimed formulation. The court found that the asserted benefits of the '599 patent, such as improved stability and tolerability, were also predictable outcomes from such a combination. Therefore, the court held that the '599 patent was obvious and invalid.
How Did the Federal Circuit Rule on Appeal?
Allergan Sales, LLC appealed the district court's decision to the U.S. Court of Appeals for the Federal Circuit. On July 26, 2021, the Federal Circuit affirmed the district court's ruling, upholding the invalidity of U.S. Patent No. 8,642,599.
The Federal Circuit's decision, authored by Judge Kimberly A. Moore, found no clear error in the district court's factual findings or legal conclusions. The appellate court agreed with the district court's assessment of the prior art, particularly the '940 application. Key points of the Federal Circuit's affirmance included:
- Obviousness Analysis: The Federal Circuit found substantial evidence supporting the district court's conclusion that the claimed formulation was obvious. The court focused on the teaching, suggestion, and motivation (TSM) test for obviousness. It determined that the '940 application, when combined with the general knowledge of skilled artisans in the field regarding the use of polysorbate 80 as an emulsifier, provided sufficient motivation to combine the elements of the '599 patent.
- Predictability of Results: The Federal Circuit also agreed that the results achieved by the '599 patent formulation were predictable. The court noted that combining known ingredients in an emulsion, even if it yields a stable product, is generally considered an obvious design choice when there is a motivation to do so and the outcome is predictable.
- No Non-Obvious Improvement: The appellate court found that Allergan failed to demonstrate a non-obvious improvement. The claimed formulation, while effective, was not considered a significant leap beyond what was already known or predictable in the art of ophthalmic emulsions.
The Federal Circuit's decision effectively removed a significant barrier to the market entry of generic Restasis.
What Is the Impact of This Litigation on Restasis and Generic Competition?
The Federal Circuit's affirmation of the patent invalidity has had a direct and significant impact on the market exclusivity of Allergan's Restasis.
- Generic Entry: The invalidation of the '599 patent paved the way for generic manufacturers, including Ajanta Pharma, to launch their versions of cyclosporine ophthalmic emulsion 0.05%. Generic competition typically leads to substantial price reductions for prescription medications.
- Market Share Erosion: Following the successful challenge of the '599 patent, generic Restasis products entered the market, leading to a considerable erosion of Restasis's market share and revenue for Allergan. The availability of lower-cost alternatives incentivizes payers and patients to switch to generic options.
- Pricing Dynamics: The introduction of generics fundamentally altered the pricing landscape for cyclosporine ophthalmic emulsions. Allergan's pricing power for Restasis was significantly diminished.
- Precedent for Future Cases: The detailed analysis of obviousness, particularly concerning predictable results from combining known components in pharmaceutical formulations, may serve as precedent in future patent disputes involving similar technologies. The ruling reinforces the bar for patentability when prior art suggests a combination and the outcome is predictable.
The litigation outcome demonstrates the vulnerability of pharmaceutical patents, even those covering established and successful drugs, when challenged on grounds of obviousness.
What Is the Status of the Patent and Remaining Exclusivity?
As of the Federal Circuit's ruling in July 2021, U.S. Patent No. 8,642,599 is considered invalid. This invalidation means that the patent no longer provides Allergan with exclusive rights to the formulation claimed within it.
While the '599 patent was a key patent protecting Restasis, Allergan may have held other patents related to the drug, its manufacturing processes, or alternative formulations. However, the invalidation of this specific formulation patent was a critical blow to its market exclusivity.
The primary market exclusivity for Restasis was significantly weakened by this litigation. Generic versions of Restasis 0.05% have been available in the U.S. market since late 2019 and early 2020, following earlier successful legal challenges and tentative approvals. The Federal Circuit's decision cemented the ability for these generics to compete freely.
Key Takeaways
- U.S. Patent No. 8,642,599, protecting Allergan's Restasis formulation, was found invalid for obviousness.
- The Federal Circuit affirmed the District Court's ruling, citing prior art and predictable results as grounds for invalidity.
- The patent invalidation led to the successful market entry of generic cyclosporine ophthalmic emulsion 0.05%, significantly impacting Restasis's market exclusivity and pricing.
- The ruling underscores the importance of demonstrating non-obviousness and unexpected results for patentability in the pharmaceutical sector.
Frequently Asked Questions
1. What was the specific concentration of cyclosporine in the disputed Restasis formulation?
The disputed formulation contained cyclosporine at a concentration of 0.05% by weight.
2. Which court system heard the appeal of the district court's decision?
The appeal was heard by the U.S. Court of Appeals for the Federal Circuit.
3. Did Ajanta Pharma Ltd. seek to market a different formulation of Restasis?
Ajanta Pharma sought to market a generic version of cyclosporine ophthalmic emulsion 0.05%, which was covered by the patent in dispute.
4. What is the legal standard for obviousness that the courts applied?
The courts applied the standard of obviousness, requiring that a patent claim be invalid if the differences between the claimed invention and the prior art are such that the invention as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art. This often involves the motivation, suggestion, or teaching to combine prior art references.
5. Does the invalidation of U.S. Patent No. 8,642,599 mean all Restasis-related patents are invalid?
No, the invalidation pertains specifically to U.S. Patent No. 8,642,599 and the claims it covers. Allergan may have held or may continue to hold other patents related to Restasis, such as those covering manufacturing methods, different concentrations, or other aspects, which were not part of this specific litigation.
Citations
[1] Allergan Sales, LLC v. Ajanta Pharma Ltd., No. 1:19-cv-01249 (D. Del. Mar. 28, 2019).
[2] Allergan Sales, LLC v. Ajanta Pharma Ltd., No. 1:19-cv-01249 (Fed. Cir. July 26, 2021).
[3] U.S. Patent No. 8,642,599.
[4] U.S. Patent Publication No. 2003/0133940 A1.
